Skip to content
thestock.space

On 6 Nov 2026, Zeal Aqua was priced at ₹10.64, or 9.1× trailing earnings, and the shares are 40% below their 52-week high. Sales and net profit grew 23% and 26% a year over 3 years, with ROCE of 34% and ROE of 15%. Debt is 1.80× equity. It is a small-cap company with a market cap of ₹134 Cr; the shares fell 4.1% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹10.45
Day high
₹11.00
Day low
₹10.05
Prev. close
₹10.15
Volume
1.3 L

Health check

2 good · 1 fair · 2 to check
  • ReturnsModest

    −4.1% over the past year.

  • Price tagNo peers

    P/E 9.1, with no peers to compare.

  • GrowthStrong

    Sales +22.5%, profit +26.0% a year over 3 years.

  • ProfitabilityStrong

    ROCE 33.8%.

  • Balance sheetStretched

    Debt 1.80× equity, interest covered 1.3×.

  • Red flags3 to check

    Debt is 1.80× equity.

Computed from reported figures. Educational, not a recommendation.

Farm Products

Small cap

₹134 Cr

Defensive

Beta 0.21 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹695 Cr · profit ₹15 Cr
Market cap
₹134 Cr
Small cap
P/E
9.1
Price to book
1.30
Book value ₹8.21
Dividend yield
0.00%
ROE
14.7%
Return on equity
ROCE
33.8%
Return on capital employed
Debt to equity
1.80
Debt ₹186 Cr
EPS (TTM)
₹1.17
OPM (TTM)
4.0%
Net margin 2.1%
Sales growth
+21.8%
Latest quarter vs a year ago
Profit growth
+40.0%
Latest quarter vs a year ago
Price to sales
0.19
EV/EBITDA 6.7

Strengths and risks

Strengths

  • Return on capital employed of 33.8%.
  • Quarterly profit up 40.0% on a year ago.
  • Quarterly sales up 21.8% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Debt is 1.80× equity.
  • 40% below its 52-week high.
  • Interest coverage of only 1.3×.

Derived automatically from reported figures. Not a recommendation.

About Zeal Aqua

Zeal Aqua Limited, an aquaculture company, engages in the farming, producing, and harvesting of prawns in India and internationally. The company trades in shrimp medicines, seeds, and feeds. It also offers fish and shrimps, as well as shrimp processing units. It also exports its products. The company was incorporated in 2009 and is based in Surat, India.

Headquarters
Surat
Employees
230
Sector
Consumer Defensive
ISIN
INE819S01025

Price range

52 weeks

₹9.10₹17.80

Today

₹10.05₹11.00
Avg volume (3M)
63.9K
1-year return
minus 4.1%
From 52-week high
minus 40.2%

Peers

We couldn’t find listed peers for this company.

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
124185222137151
117174213135144
6.610.49.11.66.8
5.3%5.6%4.1%1.1%4.5%
1.71.47.87.43.2
4.765.55.15.4
1.31.31.31.31.5
2.44.510.12.63.1
35.6%33.3%25.7%21.2%29.7%
1.537.522.2
0.120.240.600.160.17

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+22.5%
Profit CAGR 3Y
+26.0%
EPS CAGR 3Y
+25.9%
ROE
14.7%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
363398510668
–+9.7%+28.2%+31.0%
340376477640
23.222.33327.7
6.4%5.6%6.5%4.1%
3.45.89.718.5
1312.822.221.3
5.355.55.2
−0−0.1−0.1–
8.210.314.919.6
13.8%19.3%32.4%28.1%
7.18.310.114.1
–+17.3%+21.6%+40.3%
0.560.660.801.12

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
12.612.612.612.6
58.166.476.590.6
136157182194
62.658.960.143.2
270295331341
34.340.23838.4
–3.9––
6.96.89.713.6
14.70.70.9
228240283288
270295331341

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
23.924.624.634.6
−1.7−10.3−10.3−2.6
−22.4−10.6−10.6−36
−0.23.73.7−4
−2.2−10.9−10.9−3.4
21.713.713.731.2

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you